![]() | |
![]() | |
Names | |
---|---|
IUPAC name N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoyl]-L-leucine | |
Systematic IUPAC name (2S)-2-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutanamido]-4-methylpentanoic acid | |
Other names Bestatin;N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl]-L-leucine | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.055.917![]() |
EC Number |
|
KEGG | |
UNII | |
| |
| |
Properties | |
C16H24N2O4 | |
Molar mass | 308.378 g·mol−1 |
Melting point | 245 °C (473 °F; 518 K) (decomposes) |
Hazards | |
GHS labelling:[2] | |
![]() | |
Warning | |
H315,H319,H335 | |
P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P362,P403+P233,P405 | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). |
Ubenimex (INN), also known more commonly asbestatin, is a competitive, reversibleprotease inhibitor. It is aninhibitor ofarginyl aminopeptidase (aminopeptidase B),[3]leukotriene A4 hydrolase (azinc metalloprotease that displays bothepoxide hydrolase andaminopeptidase activities),[4]alanyl aminopeptidase (aminopeptidase M/N),[5]leucyl/cystinyl aminopeptidase (oxytocinase/vasopressinase),[6][7] andmembrane dipeptidase (leukotriene D4 hydrolase). It is being studied for use in the treatment ofacute myelocytic leukemia[8] andlymphedema.[9]It is derived fromStreptomyces olivoreticuli.[10] Ubenimex has been found to inhibit the enzymatic degradation ofoxytocin,vasopressin,enkephalins, and various otherpeptides and compounds.[citation needed]
![]() | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |